Akari Therapeutics Plc

AKTX

$9.76

Name : Akari Therapeutics Plc

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $18,992,810.00

EPSttm :

Akari Therapeutics Plc

$9.76

1.86%

$0.185

AKTX — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.62

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

EPS Last/This Y

-9.05

EPS This/Next Y

0.4

Price

9.76

Target Price

25.5

Analyst Recom

Performance Q

-6.34

Upside

-6,107.5%

Beta

1.43

Ticker: AKTX

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	AKTX	10.98	1.70	0.00	284
2026-08-31	AKTX	10.29	1.57	0.00	293
2026-09-01	AKTX	10.37	1.5701754385965	0	293
2026-09-02	AKTX	10.3	1.57	0.00	293
2026-09-03	AKTX	11.4	1.57	0.00	293
2026-09-04	AKTX	11.74	2.42	999.99	253
2026-09-08	AKTX	10.74	2.42	999.99	253
2026-09-09	AKTX	10.1	2.55	999.99	263
2026-09-10	AKTX	10.85	2.69	999.99	273
2026-09-11	AKTX	11.34	2.69	999.99	273
2026-09-14	AKTX	10.68	2.85	1.00	285
2026-09-15	AKTX	10.04	2.85	1.00	285
2026-09-16	AKTX	9.83	2.85	1.00	285
2026-09-17	AKTX	9.73	2.85	1.00	285
2026-09-18	AKTX	9.25	2.85	1.00	285
2026-09-21	AKTX	9.4	2.85	1.00	285
2026-09-22	AKTX	10.04	N/A	N/A	0
2026-09-23	AKTX	9.75	N/A	N/A	0
2026-09-24	AKTX	10.1	0.02	999.99	63
2026-09-25	AKTX	9.69	0.02	999.99	63
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	AKTX	11.13	-	-	-5.33
2026-08-31	AKTX	10.37	-	-	-5.33
2026-09-01	AKTX	10.20	-	-	-5.33
2026-09-02	AKTX	10.00	-	-	-5.33
2026-09-03	AKTX	10.40	-	-	-5.33
2026-09-04	AKTX	11.51	-	-	-5.33
2026-09-08	AKTX	11.20	-	-	-5.33
2026-09-09	AKTX	10.65	-	-	-5.33
2026-09-10	AKTX	10.64	-	-	-5.33
2026-09-11	AKTX	10.86	-	-	-5.33
2026-09-14	AKTX	11.28	-	-	-5.33
2026-09-15	AKTX	10.01	-	-	-5.33
2026-09-16	AKTX	10.01	-	-	-5.33
2026-09-17	AKTX	9.79	-	-	-5.33
2026-09-18	AKTX	9.25	-	-	-5.33
2026-09-21	AKTX	9.28	-	-	-5.33
2026-09-22	AKTX	10.08	-	-	-5.33
2026-09-23	AKTX	9.79	-	-	-5.33
2026-09-24	AKTX	9.88	-	-	-5.33
2026-09-25	AKTX	9.76	-100.0	-	-9.05
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	AKTX	0.00	235.73	2.16
2026-08-31	AKTX	0.00	-16.26	2.16
2026-09-01	AKTX	0.00	-16.26	2.16
2026-09-02	AKTX	0.00	-16.26	2.16
2026-09-03	AKTX	0.00	-16.26	2.16
2026-09-04	AKTX	0.00	-16.26	2.16
2026-09-08	AKTX	0.00	239.56	2.16
2026-09-09	AKTX	0.00	239.56	2.16
2026-09-10	AKTX	0.00	239.56	2.16
2026-09-11	AKTX	0.00	239.56	1.73
2026-09-14	AKTX	0.00	253.05	1.73
2026-09-15	AKTX	0.00	253.05	1.73
2026-09-16	AKTX	0.00	253.05	1.73
2026-09-17	AKTX	0.00	253.05	1.73
2026-09-18	AKTX	0.00	253.05	1.73
2026-09-21	AKTX	0.00	275.34	1.73
2026-09-23	AKTX	0.00	275.34	1.73
2026-09-24	AKTX	0.00	275.34	1.73
2026-09-25	AKTX	0.00	275.34	0.62
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-2.38

Avg. EPS Est. Next Quarter

-2.11

Insider Transactions

Institutional Transactions

275.34

Beta

1.43

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.8

Target Price

25.5

P/E

Forward P/E

PEG

P/S

P/B

0.95

P/Free Cash Flow

EPS

-17.25

Average EPS Est. Cur. Y

-9.05

EPS Next Y. (Est.)

-8.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.97

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

-9.1

EPS 1 30Days Diff

-9.05

EBIT Estimation

◆ AKTX Healthcare

$10.05

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

2/20

Pullback

13/25

Volume

7/15

Valuation

12/20

TP/AR

2/10

Options

6/10

RSI

52.1

Range 1M

41.4%

Sup Dist

3.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

2/25

Growth

20/30

Estimates

0/20

Inst/Vol

6/15

Options

7/10

EPS Yr

52.3%

EPS NY

44.3%

52W%

15.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +153.7% upside

Quality

2/30

Valuation

16/30

Growth

14/25

Stability

5/10

LT Trend

3/5

Upside

+153.7%

Quality

AKTX — P/E HistoricalBiotechnology

Akari Therapeutics Plc

Sector: Healthcare

Industry: Biotechnology

Employees: 5

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

AKTX

Latest News

—

Caricamento notizie per AKTX…

stock quote shares AKTX – Akeso Inc. Stock Price stock today

news today AKTX – Akeso Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AKTX – Akeso Inc. yahoo finance google finance

stock history AKTX – Akeso Inc. invest stock market

stock prices AKTX premarket after hours

ticker AKTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AKTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y